Philippe Genereux, MD

Dr. Philippe Généreux is a clinically active interventional cardiologist, internationally recognized clinical investigator, and academic leader in structural heart disease, combining a high-volume clinical practice with major academic and research productivity. His scholarly contributions include 430 peer-reviewed publications, more than 230 scientific abstracts, and over 700 invited oral presentations worldwide. He has an h-index of 100, placing him in the 1% most cited researcher worldwide. He has been named a Clarivate Highly Cited Researcher for four consecutive years, received the TCT Young Investigator Award (2012), the American Heart Association New Jersey Researcher of the Year Award (2018), won the Best Innovation of the year at TCT (2023), and his research has been featured in The New York Times (2024).

Dr. Généreux was the architect and Global Principal Investigator of the landmark EARLY TAVR trial, which established the benefit of TAVR in patients with asymptomatic severe aortic stenosis and contributed to FDA approval, CMS reimbursement, and changes in clinical guidelines, helping redefine the treatment paradigm for these patients. He is also the Global Principal Investigator of the PROGRESS trial, the landmark randomized trial evaluating TAVR in patients with moderate aortic stenosis, further extending his research program across the spectrum of aortic stenosis. Both trials have been published in the New England Journal of Medicine (NEJM), with Dr. Généreux as the lead author.

In parallel with his clinical and academic work, Dr. Généreux is an active medical innovator and entrepreneur, serving as an inventor or co-inventor on 9 patents and as the founder or co-founder of 3 MedTech companies, with a focus on translating cardiovascular science and novel technologies into meaningful advances in patient care. Over the past 15 years, he has also served as Chief Medical Officer of 5 MedTech companies, guiding them through various stages of development, from inception and early clinical development to FDA approval and acquisition.

Dr. Généreux received his medical degree from the Université de Montréal in Montréal, Québec, Canada, and completed his cardiology and interventional cardiology training at the Université de Sherbrooke and Sacré-Cœur Hospital in Montréal, Canada. He subsequently completed an advanced fellowship in interventional cardiology and structural heart interventions at Columbia University and the Cardiovascular Research Foundation in New York City.

He currently serves on the medical staff of Atlantic Health Morristown Medical Center in New Jersey, where he is the Medical Director of the Structural Heart Program at Atlantic Health Gagnon Cardiovascular Institute.